233 related articles for article (PubMed ID: 35987175)
1. Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy.
Reily C; Rice T; Crossman DK; Rizk DV
J Autoimmun; 2022 Oct; 132():102883. PubMed ID: 35987175
[TBL] [Abstract][Full Text] [Related]
2. Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy.
Yamada K; Huang ZQ; Raska M; Reily C; Anderson JC; Suzuki H; Kiryluk K; Gharavi AG; Julian BA; Willey CD; Novak J
Kidney Dis (Basel); 2020 May; 6(3):168-180. PubMed ID: 32523959
[TBL] [Abstract][Full Text] [Related]
3. GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy.
Jemelkova J; Stuchlova Horynova M; Kosztyu P; Zachova K; Zadrazil J; Galuszkova D; Takahashi K; Novak J; Raska M
Kidney Int Rep; 2023 May; 8(5):1068-1075. PubMed ID: 37180502
[TBL] [Abstract][Full Text] [Related]
4. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
[TBL] [Abstract][Full Text] [Related]
5. Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro.
Lin L; Shen J; Wu X; You Y; Li S
J Vis Exp; 2023 Oct; (200):. PubMed ID: 37902367
[TBL] [Abstract][Full Text] [Related]
6. ST6Gal1 is up-regulated and associated with aberrant IgA1 glycosylation in IgA nephropathy: An integrated analysis of the transcriptome.
Liu Y; Wang F; Zhang Y; Jia J; Yan T
J Cell Mol Med; 2020 Sep; 24(18):10493-10500. PubMed ID: 32677771
[TBL] [Abstract][Full Text] [Related]
7. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.
Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J
J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic biomarkers for IgA nephropathy: a comparative study pre- and post-tonsillectomy.
Xie YX; He LY; Chen X; Peng XF; Ye MY; Zhao YJ; Yan WZ; Liu C; Shao J; Peng YM
Int Urol Nephrol; 2016 Nov; 48(11):1855-1861. PubMed ID: 27465795
[TBL] [Abstract][Full Text] [Related]
9. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy.
Xing Y; Li L; Zhang Y; Wang F; He D; Liu Y; Jia J; Yan T; Lin S
BMC Nephrol; 2020 Jan; 21(1):18. PubMed ID: 31941451
[TBL] [Abstract][Full Text] [Related]
10. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.
Suzuki H; Raska M; Yamada K; Moldoveanu Z; Julian BA; Wyatt RJ; Tomino Y; Gharavi AG; Novak J
J Biol Chem; 2014 Feb; 289(8):5330-9. PubMed ID: 24398680
[TBL] [Abstract][Full Text] [Related]
11. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis.
Suzuki H; Moldoveanu Z; Julian BA; Wyatt RJ; Novak J
Kidney Int Rep; 2019 Dec; 4(12):1717-1724. PubMed ID: 31844808
[TBL] [Abstract][Full Text] [Related]
13. Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.
Wang C; Ye M; Zhao Q; Xia M; Liu D; He L; Chen G; Peng Y; Liu H
Am J Nephrol; 2019; 49(4):307-316. PubMed ID: 30917363
[TBL] [Abstract][Full Text] [Related]
14. Galactosylation of IgA1 Is Associated with Common Variation in
Gale DP; Molyneux K; Wimbury D; Higgins P; Levine AP; Caplin B; Ferlin A; Yin P; Nelson CP; Stanescu H; Samani NJ; Kleta R; Yu X; Barratt J
J Am Soc Nephrol; 2017 Jul; 28(7):2158-2166. PubMed ID: 28209808
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
Liu Y; Liu X; Jia J; Zheng J; Yan T
J Transl Med; 2019 Sep; 17(1):320. PubMed ID: 31547815
[TBL] [Abstract][Full Text] [Related]
16. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
Makita Y; Suzuki H; Kano T; Takahata A; Julian BA; Novak J; Suzuki Y
Kidney Int; 2020 Feb; 97(2):340-349. PubMed ID: 31748116
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of Yiqi Yangying Heluo Formula in the Treatment of IgA Nephropathy by Affecting Gd-IgA1 Based on BAFF Molecular Level and T Lymphocyte Immunity.
Liang Y; Zeng Q; Wang XH; Yan L; Yu RH
Biomed Res Int; 2023; 2023():5124034. PubMed ID: 36660452
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
19. Cytokines and Production of Aberrantly
Person T; King RG; Rizk DV; Novak J; Green TJ; Reily C
J Interferon Cytokine Res; 2022 Jul; 42(7):301-315. PubMed ID: 35793525
[TBL] [Abstract][Full Text] [Related]
20. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
